AstraZeneca Pharma India Ltd. — Interim / Quarterly Report 2021

Nov 5, 2020

AstraZeneca ii

==> picture [87 x 67] intentionally omitted <==

==> picture [79 x 7] intentionally omitted <==

----- Start of picture text -----

Bringing science ta palie1t since 1!179
----- End of picture text -----

November 5, 2020

The Manager - Listing

BSE Limited, 1 [st ] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai 40000 l

• The Manager Listing

National Stock Exchange of India Ltd. Exchange plaza, 5[th ] Floor, Plot No.C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051

Dear Sir(s),

Sub: Outcome of the Board Meeting held on Thursday, November 5, 2020

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

At the Board meeting of the Company held on Thursday, November 5, 2020 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended September 30, 2020. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated November 5, 2020 are enclosed herewith.

Please take the same on record.

Thanking you,

For AstraZeneca Pharma India L" d�� � Company Secretary & Legal C

TEL : +91 BO 6774 8000 FAX : +91 80 6774 8857 CIN : L24231KA1979PLC003563

WEB : www.astrazeneca.com/india

FACTORY

TEL : +91 80 6774 9000

12th Mile on Bellary Road Venkatala, Kaltigenahalli Village FAX : +91 80 2846 2208 Yelahanka Bangalore - 560 063 +91 BO 6774 9628 INDIA

CORPORATE & REGO. OFFICE AstraZeneca Pharma India Ltd. P. B. No. 4525, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045, INDIA

PRADIP M Digitally signed by PRADIP M KANAKIA KANAKIA Date: 2020.11.05 15:57:16 +05'30'

. ..

AstraZeneca Phanna India Limited Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045 Statement of unaudited financial results for the quarter and six months ended 30 September 2020

Notes:

• 1 The financial resutts have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended} prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

• 2 The Company has identified 'Healthcare Segment' as ns only reportable segment in accordance with the requirements of Ind AS 108, "Operating Segments'. Accordingly no segment infonnation has been provided.

• 3 Other Income includes interest on income tax refund of Rs.153.19 lakhs (3 months ended 30 September 2019: Rs. Nit).

• 4 Impact of COVID-19 Pandemic

• The Company has been assessing the impact of COVI D-19 pandemic on its business for the current 1inancial year. Barring the slight disruption faced during the initial phase of the COV!D onset, the Company has been able to ensure smooth and continuous supply of medicines (which have been classified as essential goods by the Government) to customers. The Company has also taken the necessary measures around safety and well being of its employees, in due compliance with the applicable laws. Management has considered Its liquidny position as at 30 September 2020 and over the next twelve months and has assessed the recoverability of the carrying values of property, plant and equipment, trade receivables and inventory and has concluded that no adjustments are required to be made in respect of such assets as at 30 September 2020.

• Management has considered all possible impacts of known events arising from COVID-19 pandemic in the preparation of these financial results and believes that the current pandemic does not have a material impact on the operations and financial position of the Company.

• 5 The Code on Social Security 2000 (the 'Code') relating to employee benefits during employment and post employment benefits was approved by the Partiament and received Presidential Assent in September 2020. The Code has also been published in the Gazette of India. However, the effective date and the rules pertaining to the code are yet to be notified/framed. The Company will assess the impact of the Code when it is made effective and will record the related financial impact, W any, in the period in which lhe Code becomes effective.

• 6 Previous period's figures have been regrouped/reclassilied. where necessary, to conform with the current period's presentation for the purpose of comparability.

• 7 This statement of finanacial results was reviewed and recommended by the Audit Commiltee of the Board and subsequently approved by the Board of Directors at their respective meetings held an 05 November 2020. The Statutory Auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 30 September 2020.

==> picture [115 x 69] intentionally omitted <==

Place: Bengaluru Date: 05 November, 2020

AstraZeneca Pharma India Limited

Regd Office: Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalll, Outer Ring Road, Bangalore 560 045

Unaudited Statement of assets and liabilities

SI.No. Balance Sheet ASSETS 1 Non-current assets (a) Propery, plant and equipment (b) Right-of-use assets (c) Capital wrk-in-progress (d) Financial Assets (i)Loans (e) Current tax assets (f Deferred tax assets (g) Other non-current assets Sub-total - Non-current assets 2 Current assets (a) Inventores (b) Financial Assets (i) Trade receivables (ii) Cash and csh equivalents (iii) Bank balances other than cash and cash equivalents (iv) Loans (v) Other fnancial assets (c) Other current assets Sub-total • Current assets TOTAL -ASSETS 1 EQUITY AND LIABILITIES Equit (al Equity Share capital (b) Other Equity Sub-total - Shareholders' funds LIABILITIES Non-urrent liabilities (a)Financial Liabilities (i) Lease liabilities (bl Provisions Sub-total • Non-urrent llabilltles 2 Current liabilities (a) Financial Liabilities (i) Trade payables Total outstanding dues of micro enterprises and small enterrises Total outstanding dues of creditors other than micro enterprises and small enterprises (ii) Lease liabilities (iii) Other fnancial liabilities (bl Other current liabilities (cl Provisions (d) Current tax liability Sub-total • Current liabilities TOTAL - EQUITY AND LIABILITIES	(Rs in lakhs'
	As at As at 30 September 2020 31 March 2020 Unaudited Audited 6,701.17 6,026.64 1,090.01 1,126.42 1,179.09 2.423.59 405.67 389.67 5,037.07 4,883.87 1,596.98 1,464.45 206.58 89.37 16,216.57 16,404.01
	19,420.29 16,514.50 7,969.76 8,321.24 22,965.17 8,350.12 2,201.54 16,901.53 69.78 80.28 1,028.11 1,157.43 2,148.81 2,907.05
	55,803.46 54,232.15
	72,020.03 70 636.16 500.00 500.00 40,003.08 35,943.62 40,503.08 36,443.62
	896.28 930.01 640.79 538.47
	1,537.07 1,468.48
	101.67 15.99 17,551.72 20,955.69 285.89 254.10 5,525.42 5,617.89 1,149.79 1,233.96
	4,723.06 4,436.43 642.33 210.00
	29,979.88 **32,724.06 **
	72 020.03 70 636.16

==> picture [59 x 119] intentionally omitted <==

Astrazeneca Pharma India Limited

Regd Office: Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045 Unaudited Statement of Cash Flows for six months ended 30 September 2020

		tRs in lakhs)	tRs in lakhs)
Pariculars	Six monts ended 30 September 2020		Six months ended 30 September 2019
	Unaudited		Unaudited 6,542.52 926.79 (10.87) (595.62) - 54.11 13.70 50.46 57.90
A) Cash fow from operating activities Profit before tax Non-cash adjustments for Deprciation expense (Proft) on sale of propery, plant and equipment (net) Interest income on deposits crried at amorised cost Interest income on Income tax refund Employee stock compensation expense Unrealised foreign exchange gain (net) Allowance for expected credit loss (net) Finance cst Operating profit before working capital changes Changes in working capital: (Increase) I Decrease in trade receivables (Increase) I Decrease in inventories (Increase)/ Decrease in loans (Increase)/ Decrease in oher fnancial assets (Increase)/ Decrease in other assets IncreaseI(Decrease) in trade payables Increase/ (Decrease) in provisions Increase/ (Decrease) in other financial liabilites Increase I (Decrease) in other liabilities Cash generated from operations Income taxes paid Net cash generated from operating activities {A) 8) Cash fows from investing activities Interest income on bank deposits Proceeds from maturity of bank deposits Purchase of propery, plant and equipment, including capital work-in-progress Proceeds from sale of property, plant and equipment Net cash generated from/ (used in) from investing activities (B) C) Cash flows from fnancing activities Principal payment of !ease liabilities Finance cst on lease liabilities Interim dividend paid Tax on interim dividend paid	6,195.43 918.36 (105.92) (475.79) (153.20) 76.00 11.21 169.06 55.07 6,690.22 176.01 (2,905.78) (4.51) (0.44) 622,30 (3,323.10) 483.86 (96.33) (87.171
			7,038.99 (1,294.79) (748.77) (125.32) (551.11) 347.77 3,303.50 336.21 (183.17) (35.20)
	1,555.06 (1,421.96)		8,088.11 (1,492.64]
	133.10		6,595.47
	605.56 14,699.99 (247.00) 110.48 15,169.03		578.37 - (933.89) 18.01 1337.51]
	(132.01) (55.07) (500.00) -		(105.94) (57.90) (250.00) (51.401
Net cash generated fom/ (used inl financing activities (Cl D) Net Increase/ (decrease) in iash and cash equivalenl (A+B+C) E) Cash and cash equivalents at the beginning of the period Fl Cash and cash eauivalent at the end of the period(D+EI	(687.08) 1465.241
	14,615.05 5,792.72 8,350.12 17,324.00
	22,965,17 23,116.72

==> picture [83 x 147] intentionally omitted <==

==> picture [456 x 54] intentionally omitted <==

To

The Board of Directors AstraZeneca Pharma India Limited Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bengaluru – 560 045

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the “Company”) for the quarter and the half year ended September 30, 2020 and the year to date results for the period April 1, 2020 to September 30, 2020 which are included in the accompanying “Statement of unaudited financial results for the quarter and six months ended 30 September 2020”, “Unaudited Statement of assets and liabilities as at 30 September 2020” and “Unaudited statement of cash flows for six months ended 30 September 2020” (together referred to as the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations, 2015”), which has been initialled by us for identification purposes.

2. This Statement, which is the responsibility of the Company’s Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP Firm Registration Number: 304026E/ E-300009

PRADIP M KANAKIA Digitally signed by PRADIP M KANAKIA Date: 2020.11.05 16:00:41 +05'30'

Pradip Kanakia Partner Place: Bengaluru Membership Number: 039985 Date: November 05, 2020 UDIN: 20039985AAAACY7306

==> picture [455 x 91] intentionally omitted <==